F-star Biotechnology Competitors and Similar CompaniesClear all
F-star Biotechnology's competitors and similar companies include KemPharm, Actinium Pharmaceuticals, Juno Therapeutics and Aceragen.
 F-star Biotechnology F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology. |  KemPharm KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. |  Actinium Pharmaceuticals Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. |  Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. |  Aceragen Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates. | |
Founding Date | Founding Date 2006 | Founding Date 2006 | Founding Date 2000 | Founding Date 2013 | Founding Date 1989 |
Type | Type Private | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Cambridge, GB HQ Wien, AT Cambridge, US | Locations Kissimmee, US HQ Blacksburg, US Coralville, US Coralville, US | Locations New York, US HQ | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US | Locations Durham, US HQ |
Employees | Employees 39 | Employees 333% increase | Employees 2517% decrease | Employees 1091% decrease | Employees 3642% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 200.5 m | Valuation ($) 58.6 m | Valuation ($) N/A | Valuation ($) 3.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) £18.7m (FY, 2018) | Revenue (est.) $106.5m (FY, 2025) | Revenue (est.) $90k (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) | Revenue (est.) $4.9m (FY, 2022) |
Net income | Net income (£2.6m) (FY, 2018) | Net income $83.2m (FY, 2025) | Net income N/A | Net income ($437.1m) (FY, 2017) | Net income ($23.4m) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised $ 57.3m | Total funding raised N/A | Total funding raised $ 7m | Total funding raised $ 310m | Total funding raised $ 13.8m |
For sources of this data, please see the company profile
View Company Profiles
KemPharm
HQ
Kissimmee, US
Employees
33↑ 3% increase
KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases.
View companyActinium Pharmaceuticals
HQ
New York, US
Employees
25↓ 17% decrease
Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers.
View companyJuno Therapeutics
HQ
Seattle, US
Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
View companyAceragen
HQ
Durham, US
Employees
36↓ 42% decrease
Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
View company